DISCOVERY OF RNA-DEPENDENT RNA POLYMERASE COMPLEX (RDRP) INHIBITORS FROM SARS-COV-2 AS HITS FOR COVID-19 DRUG DEVELOPMENT

Vol 1, 2023 - 163968
Abstract
Favorite this paper
How to cite this paper?
Abstract

Emerging viruses with pandemic potential pose a constant threat to global public health. Human infection with the novel coronavirus, COVID-19, has led to an unprecedented pandemic. As of May 2023, there have been over 670 million confirmed cases and more than 6.8 million reported deaths worldwide. SARS-CoV-2, a single-stranded RNA virus with positive polarity, uses its viral genome as mRNA to synthesize viral polyproteins by ribosomes upon entering the cell. These polyproteins are then cleaved by proteases to generate non-structural proteins. Subgenomic RNAs are produced to facilitate the creation of new genomic RNAs and structural proteins, essential for forming new viruses. The viral transcription/replication process is mediated by a replicase complex consisting of subunits of non-structural proteins (nsp7-nsp12-nsp8), with the nsp12 enzyme acting as a key RNA-dependent RNA polymerase in this complex. The RNA-dependent RNA polymerase (RdRp) represents a promising target for antiviral drugs due to its exclusively viral nature and a high degree of structural conservation compared to other coronaviruses. To assess the potential for antiviral drugs, the RdRp protein (nsp12) was expressed in insect cells using the Baculovirus system and subsequently purified through three chromatography steps. The cofactor proteins were expressed in a bacterial system and purified using two-step chromatography. The RdRp complex's polymerase activity was assessed using a direct measurement technique based on SYBR Green I fluorescence, which revealed significantly enhanced efficiency of peptide chain elongation in the presence of the complex. We screened approximately 160 compounds with inhibitory potential against the replicase complex, including molecules sourced from commercial collections and our proprietary library. Among them, four compounds demonstrated promising inhibition, with IC50 values in the low micromolar range (0.9 to 6.0 µM). Differential Scanning Fluorimetry (DSF) thermal shift assays further supported the affinity of these compounds for RdRp, with significant changes in the protein's melting temperature observed upon ligand binding (3 to 20°C). These findings present hits for the development of novel RdRp inhibitors as potential antiviral lead candidates to combat emerging viral threats.

Share your ideas or questions with the authors!

Did you know that the greatest stimulus in scientific and cultural development is curiosity? Leave your questions or suggestions to the author!

Sign in to interact

Have a question or suggestion? Share your feedback with the authors!

Track
  • 3. Drug design and delivery
Keywords
SARS-CoV-2; nsp12; rdrp